Latest Insider Transactions at Supernus Pharmaceuticals, Inc. (SUPN)
This section provides a real-time view of insider transactions for Supernus Pharmaceuticals, Inc. (SUPN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of SUPERNUS PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of SUPERNUS PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 26
2025
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
SELL
Payment of exercise price or tax liability
|
Direct |
2,885
-8.67%
|
$112,515
$39.48 P/Share
|
|
Feb 26
2025
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Exercise of conversion of derivative security
|
Direct |
5,760
+14.69%
|
-
|
|
Feb 23
2025
|
Jonathan Rubin SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+10.12%
|
-
|
|
Feb 23
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Grant, award, or other acquisition
|
Direct |
1,250
+8.1%
|
-
|
|
Feb 23
2025
|
Timothy C Dec Senior Vice-President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+15.07%
|
-
|
|
Feb 23
2025
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Grant, award, or other acquisition
|
Direct |
1,875
+12.69%
|
-
|
|
Feb 22
2025
|
Jonathan Rubin SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+9.64%
|
-
|
|
Feb 22
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+7.42%
|
-
|
|
Feb 22
2025
|
Timothy C Dec Senior Vice-President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
3,500
+13.03%
|
-
|
|
Feb 22
2025
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+8.66%
|
-
|
|
Feb 22
2025
|
Frederick M. Hudson Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,369
+9.08%
|
-
|
|
Feb 22
2025
|
Georges Gemayel Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,369
+22.32%
|
-
|
|
Feb 22
2025
|
Charles W Newhall Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,369
+3.81%
|
-
|
|
Feb 22
2025
|
Bethany Sensenig Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,369
+50.0%
|
-
|
|
Feb 22
2025
|
Carrolee Barlow Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,369
+19.22%
|
-
|
|
Feb 21
2025
|
Jonathan Rubin SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
927
-10.56%
|
$36,153
$39.15 P/Share
|
|
Feb 21
2025
|
Jonathan Rubin SVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,875
+17.6%
|
-
|
|
Feb 21
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
860
-7.29%
|
$33,540
$39.15 P/Share
|
|
Feb 21
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,650
+12.27%
|
-
|
|
Feb 21
2025
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
SELL
Payment of exercise price or tax liability
|
Direct |
552
-5.76%
|
$21,528
$39.15 P/Share
|
|
Feb 21
2025
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Exercise of conversion of derivative security
|
Direct |
1,125
+10.51%
|
-
|
|
Feb 04
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Open market or private sale
|
Direct |
9,477
-48.29%
|
$369,603
$39.7 P/Share
|
|
Feb 04
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,477
+32.56%
|
$274,833
$29.61 P/Share
|
|
Jan 28
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Open market or private sale
|
Direct |
700
-6.45%
|
$27,300
$39.62 P/Share
|
|
Jan 28
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
700
+6.06%
|
$20,300
$29.61 P/Share
|
|
Jan 27
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Open market or private sale
|
Direct |
2,573
-20.22%
|
$100,347
$39.62 P/Share
|
|
Jan 27
2025
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,573
+16.82%
|
$74,617
$29.61 P/Share
|
|
Jan 22
2025
|
Frederick M. Hudson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+29.24%
|
$180,000
$9.13 P/Share
|
|
Dec 27
2024
|
Jonathan Rubin SVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,102
-7.95%
|
$38,570
$35.59 P/Share
|
|
Dec 27
2024
|
Jonathan Rubin SVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,625
+15.8%
|
-
|
|
Dec 27
2024
|
Jack A. Khattar President, CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
25,233
-1.31%
|
$883,155
$35.59 P/Share
|
|
Dec 27
2024
|
Jack A. Khattar President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
52,640
+2.64%
|
-
|
|
Dec 03
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
SELL
Open market or private sale
|
Direct |
21,495
-52.16%
|
$773,820
$36.68 P/Share
|
|
Dec 03
2024
|
Padmanabh P. Bhatt Sr. VP of IP, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,495
+34.22%
|
$515,880
$24.65 P/Share
|
|
Nov 11
2024
|
Charles W Newhall Iii Director |
SELL
Open market or private sale
|
Direct |
10,700
-7.59%
|
$385,200
$36.24 P/Share
|
|
Nov 11
2024
|
Charles W Newhall Iii Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+12.42%
|
$180,000
$9.13 P/Share
|
|
Nov 08
2024
|
Frederick M. Hudson Director |
SELL
Open market or private sale
|
Direct |
8,722
-23.5%
|
$313,992
$36.28 P/Share
|
|
Nov 08
2024
|
Jack A. Khattar President, CEO |
SELL
Open market or private sale
|
Direct |
125,000
-11.89%
|
$4,500,000
$36.29 P/Share
|
|
Nov 08
2024
|
Jack A. Khattar President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
125,000
+10.63%
|
$1,125,000
$9.13 P/Share
|
|
Nov 08
2024
|
Georges Gemayel Director |
SELL
Open market or private sale
|
Direct |
10,787
-44.76%
|
$388,332
$36.3 P/Share
|
|
Nov 08
2024
|
Georges Gemayel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,787
+30.92%
|
$118,657
$11.46 P/Share
|
|
Nov 07
2024
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
SELL
Open market or private sale
|
Direct |
15,000
-64.66%
|
$540,000
$36.98 P/Share
|
|
Nov 07
2024
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+39.27%
|
$135,000
$9.13 P/Share
|
|
Nov 07
2024
|
Jack A. Khattar President, CEO |
SELL
Open market or private sale
|
Direct |
125,000
-11.89%
|
$4,500,000
$36.68 P/Share
|
|
Nov 07
2024
|
Jack A. Khattar President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
125,000
+10.63%
|
$1,125,000
$9.13 P/Share
|
|
Nov 07
2024
|
Georges Gemayel Director |
SELL
Open market or private sale
|
Direct |
14,213
-51.63%
|
$511,668
$36.62 P/Share
|
|
Nov 07
2024
|
Georges Gemayel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
14,213
+34.05%
|
$156,343
$11.46 P/Share
|
|
Sep 13
2024
|
Georges Gemayel Director |
SELL
Open market or private sale
|
Direct |
13,886
-32.74%
|
$430,466
$31.33 P/Share
|
|
Sep 13
2024
|
Georges Gemayel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+30.02%
|
$110,000
$11.46 P/Share
|
|
Sep 03
2024
|
Jack A. Khattar President, CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,045
-1.07%
|
$341,530
$34.9 P/Share
|